SCHEDULE 13G/A: Franklin Resources and Affiliates Disclose 18.1% Stake in Benitec Biopharma

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have reported a combined beneficial ownership of 18.1% of Benitec Biopharma Inc.'s common stock, including shares from warrant exercises.

Summary

• Franklin Resources, Inc. and its subsidiary, Franklin Advisers, Inc., have filed an Amendment No. 4 to Schedule 13G, disclosing their beneficial ownership in Benitec Biopharma Inc.
• As of December 31, 2024, Franklin Resources, Inc. and Franklin Advisers, Inc. each beneficially own 4,493,691 shares of Benitec Biopharma Inc. Common Stock.
• This aggregate amount represents 18.1% of the class of securities.
• The reported beneficial ownership includes 1,554,404 shares of Common Stock that are issuable upon the exercise of warrants.
• Franklin Advisers, Inc. holds sole voting and sole dispositive power over all 4,493,691 shares.
• Two specific funds managed by Franklin affiliates hold significant interests: Franklin Biotechnology Discovery Fund (a series of Franklin Strategic Series) holds 1,607,896 shares (6.5% of the class), and Franklin Biotechnology Discovery Fund (a sub-fund of Franklin Templeton Investment Funds) holds 2,885,722 shares (11.7% of the class).
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Benitec Biopharma Inc.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing (Schedule 13G) reporting beneficial ownership. It contains no subjective language or forward-looking statements that would indicate a positive or negative sentiment beyond the neutral act of disclosure itself.

Positives

• A significant institutional investor, Franklin Resources, Inc., maintains a substantial stake (18.1%) in Benitec Biopharma Inc., which could be viewed as a vote of confidence.
• The ownership includes shares from warrant exercises, indicating potential long-term interest or a prior investment strategy.

Future Outlook

NA

Management Comments

• The filing certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates continued institutional investment in the biotechnology sector, specifically in Benitec Biopharma Inc., by a major asset manager. Such disclosures are standard for significant ownership stakes and reflect ongoing portfolio management activities within the biopharmaceutical industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Franklin Resources, Inc. may be viewed positively by other shareholders as it indicates institutional confidence or liquidity.
• Management: Awareness of a large institutional holder may influence management's strategic decisions, though the filing explicitly states the holding is not for control purposes.

Key Dates

Keywords

Benitec Biopharma Inc., Franklin Resources Inc., Franklin Advisers Inc., Schedule 13G, beneficial ownership, common stock, institutional investment, warrants, biopharma, SEC filing, investment management